CA2476773C - Monoclonal antibodies against extracellular loops of c5ar - Google Patents

Monoclonal antibodies against extracellular loops of c5ar Download PDF

Info

Publication number
CA2476773C
CA2476773C CA2476773A CA2476773A CA2476773C CA 2476773 C CA2476773 C CA 2476773C CA 2476773 A CA2476773 A CA 2476773A CA 2476773 A CA2476773 A CA 2476773A CA 2476773 C CA2476773 C CA 2476773C
Authority
CA
Canada
Prior art keywords
antibody
c5ar
functional fragment
binding
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2476773A
Other languages
English (en)
French (fr)
Other versions
CA2476773A1 (en
Inventor
Charles Reay Mackay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G2 Therapies Ltd
Original Assignee
G2 Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G2 Therapies Ltd filed Critical G2 Therapies Ltd
Publication of CA2476773A1 publication Critical patent/CA2476773A1/en
Application granted granted Critical
Publication of CA2476773C publication Critical patent/CA2476773C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
CA2476773A 2002-01-25 2003-01-24 Monoclonal antibodies against extracellular loops of c5ar Expired - Fee Related CA2476773C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35096102P 2002-01-25 2002-01-25
US60/350,961 2002-01-25
PCT/AU2003/000084 WO2003062278A1 (en) 2002-01-25 2003-01-24 MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR

Publications (2)

Publication Number Publication Date
CA2476773A1 CA2476773A1 (en) 2003-07-31
CA2476773C true CA2476773C (en) 2013-05-28

Family

ID=27613447

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2476773A Expired - Fee Related CA2476773C (en) 2002-01-25 2003-01-24 Monoclonal antibodies against extracellular loops of c5ar

Country Status (11)

Country Link
US (3) US8071096B2 (enExample)
EP (2) EP2371861B1 (enExample)
JP (2) JP4559081B2 (enExample)
CN (2) CN1642983A (enExample)
AU (3) AU2003202297C1 (enExample)
CA (1) CA2476773C (enExample)
DK (1) DK2371861T3 (enExample)
ES (2) ES2646792T3 (enExample)
NZ (1) NZ534399A (enExample)
WO (1) WO2003062278A1 (enExample)
ZA (1) ZA200406347B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003202297C1 (en) 2002-01-25 2006-05-18 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
US7455837B2 (en) * 2002-11-05 2008-11-25 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
AU2007288118A1 (en) 2006-08-22 2008-02-28 G2 Inflammation Pty Ltd Anti-C5aR antibodies with improved properties
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
WO2008109742A1 (en) * 2007-03-06 2008-09-12 Novo Nordisk A/S Modulation of complement system activation for treatment of bleeding-related inflammation
CA2718588A1 (en) * 2008-02-19 2009-08-27 The Trustees Of The University Of Pennsylvania Complement inhibitors as therapeutic agents for treatment of cancer
KR20100117120A (ko) 2008-02-20 2010-11-02 지투 인플레메이션 피티와이 엘티디 인간화된 항-Ｃ5ａＲ 항체
NZ597259A (en) 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
WO2011100477A2 (en) * 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
RU2616881C2 (ru) * 2011-06-06 2017-04-18 Ново Нордиск А/С Терапевтические антитела
PT2888593T (pt) 2012-08-21 2018-12-12 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilizações dos mesmos
DK2994488T3 (da) * 2013-05-08 2022-10-03 Novo Nordisk As Anvendelse af c5ar-antagonister
CN105744996B (zh) * 2013-11-28 2018-10-19 通用电气医疗集团生物工艺研发股份公司 发酵饮料的稳定
EP3119802B1 (en) * 2014-03-20 2019-12-04 InflaRx GmbH Inhibitors of c5a for the treatment of viral pneumonia
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
JP7617012B2 (ja) * 2019-03-14 2025-01-17 モルフォシス・アーゲー Ｃ５ａＲを標的とする抗体
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
EP4196501A1 (en) 2020-08-12 2023-06-21 Innate Pharma Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JPH02262599A (ja) * 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1994007921A1 (en) 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) * 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5861272A (en) * 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
JPH08109200A (ja) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd 抗Ｃ５ａレセプター抗体、その製造法および用途
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP0832231A2 (en) 1995-06-05 1998-04-01 Incyte Pharmaceuticals, Inc. A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
JP2001511645A (ja) 1997-01-31 2001-08-14 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトＣ５ａ様受容体
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
AU2002231194A1 (en) 2000-11-07 2002-05-21 Genetics Institute, Llc G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2002059263A2 (en) 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
EP1438325B1 (en) 2001-09-27 2009-12-30 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
AU2003202297C1 (en) 2002-01-25 2006-05-18 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
JP2006513702A (ja) 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Ｇタンパク質共役受容体およびその使用
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
AU2004304665B2 (en) 2003-12-24 2009-03-12 Novo Nordisk A/S Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
JP2010501165A (ja) 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
AU2007288118A1 (en) 2006-08-22 2008-02-28 G2 Inflammation Pty Ltd Anti-C5aR antibodies with improved properties
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
EP2203180B1 (en) 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
KR20100117120A (ko) 2008-02-20 2010-11-02 지투 인플레메이션 피티와이 엘티디 인간화된 항-Ｃ5ａＲ 항체
WO2010000864A1 (en) 2008-07-04 2010-01-07 Novo Nordisk A/S Method for producing monoclonal antibodies
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative

Also Published As

Publication number Publication date
US20130129717A1 (en) 2013-05-23
US20050244406A1 (en) 2005-11-03
JP2005535562A (ja) 2005-11-24
US8071096B2 (en) 2011-12-06
AU2003202297C1 (en) 2006-05-18
US20120121584A1 (en) 2012-05-17
CN102659945A (zh) 2012-09-12
EP2371861A1 (en) 2011-10-05
JP4559081B2 (ja) 2010-10-06
CN102659945B (zh) 2016-12-21
AU2003202297B2 (en) 2005-11-17
WO2003062278A1 (en) 2003-07-31
US8673305B2 (en) 2014-03-18
DK2371861T3 (da) 2017-11-20
JP2010051323A (ja) 2010-03-11
ES2561828T3 (es) 2016-03-01
EP1476469A4 (en) 2005-11-23
CA2476773A1 (en) 2003-07-31
ES2646792T3 (es) 2017-12-18
JP5202501B2 (ja) 2013-06-05
CN1642983A (zh) 2005-07-20
US8221757B2 (en) 2012-07-17
AU2009238340A1 (en) 2009-12-10
AU2006200320A1 (en) 2006-02-16
EP1476469A1 (en) 2004-11-17
NZ534399A (en) 2008-08-29
ZA200406347B (en) 2006-06-28
EP1476469B1 (en) 2015-11-18
EP2371861B1 (en) 2017-08-09

Similar Documents

Publication Publication Date Title
US8221757B2 (en) Monoclonal antibodies against extracellular loops of C5aR
EP3798230B1 (en) Therapeutic antibodies
JP5162587B2 (ja) 改良された特性を持つ坑−Ｃ５ａＲ抗体
AU2003202297A1 (en) Anti-C5aR antibodies and uses thereof
KR20120059611A (ko) 인간 프로테아제-활성화된 수용체-2에 대한 고친화도 인간 항체들
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
JP2024545174A (ja) 抗ｃｄ２４抗体およびその使用
WO2021098822A1 (zh) 一种双特异性抗体
US20230013784A1 (en) Anti-cea antibody and application thereof
RU2741802C2 (ru) АНТИТЕЛО К Myl9
WO2024012513A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
TW202500589A (zh) 抗bdca2抗體
HK40045557A (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
HK40059424B (zh) 抗cd79b抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170124